GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

zolucatetide   Click here for help

GtoPdb Ligand ID: 14191

Compound class: Peptide
Comment: In >10% of solid tumours aberrant Wnt/β-catenin signaling is a recognised driver of resistance to immunotherapy and is associated with poor prognosis. Zolucatetide (FOG-001; Parabilis Medicines) is a cyclic peptide inhibitor of the interaction between β-catenin and the T cell (transcription) factor TCF4 [1]. This action disrupts Wnt signaling, and is proposed for anti-tumour potential. The peptide is highly modified to optimise target engagement and pharmacokinetics.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@@H](C(=O)N)NC(=O)[C@@H]1CCC(=O)NCCCC[C@H]2C(=O)N[C@]3(CCN(C3)C(=O)OCCC/C=C/CCC[C@]4(CCC/C=C\C[C@]5(CCCN5C(=O)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)(C)C)C(=O)N4)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC6=CC=CC(=C6)C(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N2)C(=O)N[C@@H](CC8=CSC=C8)C(=O)N[C@@H](CC9=CSC%10=C9C=CC=C%10)C(=O)N1
Isomeric SMILES C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)CC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@]3(CCN(C3)C(=O)OCCC/C=C/CCC[C@]4(CCC/C=C\C[C@]5(CCCN5C(=O)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC(C)(C)C)CC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(C(=O)N1)(C)C)CC6=CC(=CC=C6)C(=O)O)CC(=O)O)NC2=O)CC7=CSC=C7)CC8=CSC9=CC=CC=C98)C(=O)N[C@@H](C)C(=O)N)CC%10=CC=CC=C%10
InChI InChI=1S/C102H134N18O25S2/c1-59(81(103)127)105-83(129)69-35-36-78(122)104-43-24-20-33-68-89(135)118-101(95(142)113-71(51-64-37-47-146-56-64)85(131)111-73(86(132)108-69)52-66-57-147-77-34-19-18-32-67(66)77)42-45-119(58-101)97(144)145-46-25-14-10-9-11-21-38-100(39-22-12-13-23-40-102(41-27-44-120(102)61(3)121)96(143)115-75(54-80(125)126)88(134)112-76(91(137)117-100)55-98(4,5)6)94(141)114-74(53-79(123)124)87(133)110-72(50-63-30-26-31-65(48-63)92(138)139)90(136)116-99(7,8)93(140)106-60(2)82(128)109-70(84(130)107-68)49-62-28-16-15-17-29-62/h9-10,13,15-19,23,26,28-32,34,37,47-48,56-57,59-60,68-76H,11-12,14,20-22,24-25,27,33,35-36,38-46,49-55,58H2,1-8H3,(H2,103,127)(H,104,122)(H,105,129)(H,106,140)(H,107,130)(H,108,132)(H,109,128)(H,110,133)(H,111,131)(H,112,134)(H,113,142)(H,114,141)(H,115,143)(H,116,136)(H,117,137)(H,118,135)(H,123,124)(H,125,126)(H,138,139)/b10-9+,23-13-/t59-,60-,68-,69-,70-,71-,72-,73-,74-,75-,76-,100-,101-,102-/m0/s1
InChI Key QZAJMBQKMDKREN-XAAYEZHBSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. White BH, La DS, Alfaro-Lopez LJ, Ortet PC, Cappicci SI, Li Z, Mcgee JH, Tremblay MR, Verdine GL, Si Y et al.. (2022)
Stapled peptides and methods thereof.
Patent number: WO2022261257A1. Assignee: Fog Pharmaceuticals, Inc.. Priority date: 08/06/2022. Publication date: 15/12/2022.